On July 28, the Committee on the Guidance on PFAS Testing and Health Outcomes at the National Academies of Sciences, Engineering, and Medicine released a report on “Guidance on PFAS Exposure, Testing, and Clinical Follow-Up.” Commissioned by ATSDR and NIEHS, the report offers feedback on “principles for biological testing and clinical evaluation, given substantial uncertainty about the health effects or the value of such measures in informing care.” The committee also reviewed the human health literature on PFAS and offered feedback on exposure reduction and advice on changes to ATSDR’s current clinical guidance. The report suggests blood levels below which additional clinical care is not needed, levels where clinicians should consider prioritizing certain evaluations, and levels where clinicians should assess additional testing.